SCHEMBL3585374

SCHEMBL3585374

Cc1c(C(=O)N(C)Cc2ccc(Cl)cc2F)[nH]c(C(N)=O)c1S(=O)(=O)c1ccccc1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR3C1 P04150 1/20 0.38
PGR P06401 1/20 0.38
NR3C2 P08235 1/20 0.38
AR P10275 1/20 0.38
PTGDR2 Q9Y5Y4 1/20 0.37
HPGD P15428 2/20 0.36
NPSR1 Q6W5P4 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
MAP2 P11137 1/20 0.35
PTGS2 P35354 1/20 0.35
FFAR2 O15552 1/20 0.35
MEN1 O00255 3/20 0.34
KMT2A Q03164 3/20 0.34
HAO1 Q9UJM8 1/20 0.34
CRHBP P24387 1/20 0.33
CRHR2 Q13324 1/20 0.33
ATM Q13315 1/20 0.33
LIMK2 P53671 1/20 0.33
CXCR3 P49682 1/20 0.33
LMNA P02545 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3586731 0.92 HTR6 (0.37) NR3C1PGRNR3C2ARPTGDR2
SCHEMBL3589589 0.92 MAP2 (0.35) NR3C1PGRNR3C2ARPTGDR2
SCHEMBL3581282 0.91 NR3C1 (0.35) NR3C1PGRNR3C2ARPTGDR2
SCHEMBL3576472 0.91 NPSR1 (0.43) HPGDNPSR1L3MBTL1PTGS2FFAR2
SCHEMBL3578045 0.89 PTGDR2 (0.35) NR3C1PGRNR3C2ARPTGDR2
SCHEMBL3592623 0.89 MEN1 (0.43) MEN1KMT2AATMLIMK2KDM4E
SCHEMBL3579136 0.89 MAP2 (0.34) NR3C1PGRNR3C2ARPTGDR2
SCHEMBL3581876 0.87 NR1H2 (0.41) PTGDR2HPGDNPSR1L3MBTL1MEN1
SCHEMBL3586766 0.86 KMT2A (0.38) PTGDR2MAP2MEN1KMT2AATM
SCHEMBL3587819 0.85 CRHBP (0.37) PTGDR2HPGDNPSR1L3MBTL1MAP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100113421-A1 NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MERCK SHARP & DOHME CORP. 2010-05-06 US claimed
EP-2076492-A2 NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS Merck & Co., Inc. (US) 2009-07-08 EP claimed
WO-2008054605-A2 NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MERCK & CO., INC. (US) 2008-05-08 WO claimed
US-20100113421-A1 NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MERCK SHARP & DOHME CORP. 2010-05-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100113421-A1 NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS RTF1, RNGTT, POLR2E NR3C1 1580/4885PGR 1579/4885NR3C2 2289/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.